Takeda Pharmaceutical Company Limited
TAK
$13.88
$0.010.07%
NYSE
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -78.22% | 286.26% | -6.18% | -108.64% | -15.23% |
| Total Depreciation and Amortization | -3.27% | 2.38% | -1.31% | 1.13% | 1.02% |
| Total Amortization of Deferred Charges | -- | -- | -- | 13.61% | -- |
| Total Other Non-Cash Items | 314.10% | -727.82% | 28.00% | 174.86% | -39.16% |
| Change in Net Operating Assets | 151.74% | -45.28% | 23.47% | -63.10% | -409.10% |
| Cash from Operations | 153.62% | 37.29% | 62.29% | -15.47% | -63.02% |
| Capital Expenditure | 7.31% | -27.05% | -10.05% | -10.96% | -34.38% |
| Sale of Property, Plant, and Equipment | -97.10% | -99.66% | -27.97% | -99.80% | 1,599.92% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | 74,856.49% | 596.12% | 119.42% | -- |
| Other Investing Activities | -143.99% | 2.73% | 59.27% | 92.09% | -105.79% |
| Cash from Investing | -48.59% | -20.54% | 48.23% | 87.50% | -53.98% |
| Total Debt Issued | -76.47% | -- | 141.73% | -102.61% | -- |
| Total Debt Repaid | -429.37% | -247.85% | 29.47% | 86.88% | 63.75% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | 19.09% | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -1.83% | 1.37% | 6.99% | 21.94% | -2.38% |
| Other Financing Activities | -20.11% | -222.84% | 211.17% | -38.15% | 17.01% |
| Cash from Financing | -549.44% | 23.96% | 582.15% | -686.16% | 78.53% |
| Foreign Exchange rate Adjustments | 810.87% | -1,115.27% | 2.73% | 4,538.96% | 68.94% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -1,089.38% | 3,039.15% | 240.79% | 199.60% | 74.90% |